2,2′-Dihydroxy-4,4′-dimethoxybenzophenone-5,5′-disulphonic acid sodium salt

We are 2,2′-Dihydroxy-4,4′-dimethoxybenzophenone-5,5′-disulphonic acid sodium salt CAS:76656-36-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 2,2'-Dihydroxy-4,4'-dimethoxybenzophenone-5,5'-disulphonic acid sodium salt
Other Name: Disodium 4-hydroxy-5-(2-hydroxy-4-methoxy-5-sulfonatobenzoyl)-2-methoxybenzenesulfonate;Disodium 2,2'-dihydroxy-4,4'-dimethoxy-5,5'-disulfobenzophenone
CAS No: 76656-36-5
MF: C15H12Na2O11S2
MW: 478.35900
Melting point: 350°C (dec.)
UN Number: UN1325
UN Proper Shipping Name: FLAMMABLE SOLID, ORGANIC, N.O.S.
Transport hazard class: 4.1
Packing group: II
 
Specification
Appearance: Light yellow crystalline powder
Assay: ≥98%
Hazen: ≤6.0
K value(330nm): ≥16.0
 
Application
Widely used in water-soluble cosmetics, water-soluble inks, paints, paints.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

2,2'-Dihydroxy-4,4'-dimethoxybenzophenone-5,5'-disulphonic acid sodium salt


Related News: The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds.126534-31-4 ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States.32955-21-8 “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.6-(Trifluoromethyl)nicotinic acid Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday.Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).

Related Products
Product Name
chloromethyl carbonochloridate View Details
3-Amino-4-fluorobenzoic acid View Details
4-Isothiocyanato-2-(trifluoromethyl)benzonitrile View Details
5-Fluoro-2-hydroxypyridine manufacturer Thiophene-3,4-Dicarboxylic Acid manufacturer 3-Cyanobenzylchloride manufacturer 2-Fluoroanisole manufacturer dehydroepiandrosterone manufacturer